Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

(2018) Michal Sarfaty et al.   EUROPEAN UROLOGY

Pembrolizumab for the treatment of non-small cell lung cancer

(2017) Mirte Muller et al.   Expert Review of Anticancer Therapy

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

(2017) Arnaud Scherpereel et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

(2017) Bingshan Liu et al.   Journal of Hematology & Oncology

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

(2017) Kevin J Harrington et al.   LANCET ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States

(2017) Min Huang et al.   PHARMACOECONOMICS

Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal

(2017) Luis Silva Miguel et al.   VALUE IN HEALTH

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance

(2017) Lesley-Ann Martin et al.   Nature Communications

Biosimilars—Curb Your Enthusiasm

(2017) Y. Tony Yang et al.   JAMA Oncology

Immune checkpoint inhibitors for cancer treatment

(2016) Junsik Park et al.   ARCHIVES OF PHARMACAL RESEARCH

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

(2016) David Cella et al.   LANCET ONCOLOGY

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

(2016) Johan F Vansteenkiste et al.   LANCET ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

(2016) Jun Wang et al.   OncoTargets and Therapy

Checkpoint inhibitors in lung cancer: latest developments and clinical potential

(2016) Gustavo Schvartsman et al.   Therapeutic Advances in Medical Oncology

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia

(2015) Simona Soverini et al.   Clinical Lymphoma Myeloma & Leukemia

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

(2015) Daniel Sanghoon Shin et al.   CURRENT OPINION IN IMMUNOLOGY

Immuno-regulatory antibodies for the treatment of cancer

(2015) Jamie Honeychurch et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

(2015) Gregory A. Masters et al.   JOURNAL OF CLINICAL ONCOLOGY

What is a new drug worth? An innovative model for performance-based pricing

(2014) G. Dranitsaris et al.   EUROPEAN JOURNAL OF CANCER CARE

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?

(2014) George Dranitsaris et al.   Applied Health Economics and Health Policy

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Victories and deceptions in tumor immunology

(2013) Guido Kroemer et al.   OncoImmunology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions

(2009) Fiona M. Clement et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY